VR Logo

Rallybio Corporation (RLYB) download report


Healthcare | Biotechnology & Pharma Research

Rallybio Corporation (RLYB) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases.

IPO Date: 29-Jul-2021

Co-Founder, CEO & Chairman: Dr. Martin W. MacKay Ph.D.

Co- Founder, Pres, COO & Chief Scientific Officer: Dr. Stephen Uden M.B, M.D.

Listing: NASDAQ: RLYB

Country: United States

Headquarters: New Haven, CT

Website: https://www.rallybio.com

Key Facts

Market cap: $226.20 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-47.90 Mln

Cash: $161.41 Mln

Total Debt: $0.67 Mln

Insider's Holding: 7.48%

Liquidity: Low

52 Week range: $5.90 - 25.78

Shares outstanding: 32,131,000

Stock Performance

Time Period Rallybio (RLYB) S&P BSE Sensex S&P Small-Cap 600
YTD-20.96-9.18-18.78
1 month-42.00-4.78-8.00
3 months8.02-9.66-13.65
1 Year--0.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022